Sydney, Australia 11 October 2018 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Prof Jason S. Lewis has joined their scientific advisory board.
Jason S. Lewis, PhD, serves as Vice Chair for Research in the Department of Radiology at Memorial Sloan Kettering Cancer Center (MSK), Chief of MSK’s Radiochemistry & Imaging Sciences Service, and Director of MSK’s Radiochemistry and Molecular Imaging Probe Core Facility. He is head of a laboratory in the Sloan Kettering Institute’s Molecular Pharmacology Program and a Professor at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences and at Weill Cornell Medical College. Prof Lewis holds a PhD from The University of Kent (UK) and has published over 180 papers, books, book chapters, and reviews in the field of cancer imaging. He has served as the President of the World Molecular Imaging Society (2014-2015) and has received a Distinguished Investigator Award from the Academy of Radiology Research, was named a Fellow of the World Molecular Imaging Society and was the 2017 SNMMI Michael J. Welch Award winner.
Prof Lewis commented on his appointment: “I have personally had a long history of working with copper isotopes, and Clarity’s theranostic approach to treating cancer by employing copper radioisotopes for imaging and therapy is at the forefront of drug development. I am excited to join Clarity’s scientific advisory board and looking forward to working with the Clarity team on progressing Clarity’s clinical pipeline to improve treatment outcomes for cancer patients around the world.”
Clarity’s Executive Chairman, Dr Alan Taylor commented “We are honoured to have Prof Lewis on our scientific advisory board. His extensive knowledge of the radiopharmaceutical field and experience of working with a number of promising theranostic (diagnostic and therapy) agents will prove invaluable for Clarity’s pipeline development.”
Media Contact
Dr Alan Taylor
Executive Chairman
Ph: +61 (0)413 871 165
E: ataylor@claritypharm.com
About Clarity
Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.
